253 related articles for article (PubMed ID: 15058750)
1. Evaluation of the comfort of Alphagan P compared with Alphagan in irritated eyes.
Mundorf T; Wilcox KA; Ousler GW; Welch D; Abelson MB
Adv Ther; 2003; 20(6):329-36. PubMed ID: 15058750
[TBL] [Abstract][Full Text] [Related]
2. Brimonidine purite 0.1% versus brinzolamide 1% as adjunctive therapy to latanoprost in patients with glaucoma or ocular hypertension.
Day DG; Hollander DA
Curr Med Res Opin; 2008 May; 24(5):1435-42. PubMed ID: 18402717
[TBL] [Abstract][Full Text] [Related]
3. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension.
Katz LJ
J Glaucoma; 2002 Apr; 11(2):119-26. PubMed ID: 11912359
[TBL] [Abstract][Full Text] [Related]
4. Brimonidine-purite 0.1% versus brimonidine-purite 0.15% twice daily in glaucoma or ocular hypertension: a 12-month randomized trial.
Cantor LB; Safyan E; Liu CC; Batoosingh AL
Curr Med Res Opin; 2008 Jul; 24(7):2035-43. PubMed ID: 18534052
[TBL] [Abstract][Full Text] [Related]
5. A 3-month comparison of efficacy and safety of brimonidine-purite 0.15% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
Mundorf T; Williams R; Whitcup S; Felix C; Batoosingh A
J Ocul Pharmacol Ther; 2003 Feb; 19(1):37-44. PubMed ID: 12648302
[TBL] [Abstract][Full Text] [Related]
6. Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension.
Sharpe ED; Day DG; Beischel CJ; Rhodes JS; Stewart JA; Stewart WC
Br J Ophthalmol; 2004 Jul; 88(7):953-6. PubMed ID: 15205246
[TBL] [Abstract][Full Text] [Related]
7. Brimonidine hypersensitivity when switching between 0.2% and 0.15% formulations.
Sullivan-Mee M; Pensyl D; Alldredge B; Halverson K; Gerhardt G; Qualls C
J Ocul Pharmacol Ther; 2010 Aug; 26(4):355-60. PubMed ID: 20653479
[TBL] [Abstract][Full Text] [Related]
8. Brimonidine Purite and bimatoprost compared with timolol and latanoprost in patients with glaucoma and ocular hypertension.
Netland PA; Michael M; Rosner SA; Katzman B; Macy JI
Adv Ther; 2003; 20(1):20-30. PubMed ID: 12772815
[TBL] [Abstract][Full Text] [Related]
9. Brimonidine 0.2% versus brimonidine Purite 0.15% in Asian ocular hypertension.
Kim CY; Hong S; Seong GJ
J Ocul Pharmacol Ther; 2007 Oct; 23(5):481-6. PubMed ID: 17900227
[TBL] [Abstract][Full Text] [Related]
10. Formulation effects on ocular absorption of brimonidine in rabbit eyes.
Acheampong AA; Small D; Baumgarten V; Welty D; Tang-Liu D
J Ocul Pharmacol Ther; 2002 Aug; 18(4):325-37. PubMed ID: 12222763
[TBL] [Abstract][Full Text] [Related]
11. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
LeBlanc RP
Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
[TBL] [Abstract][Full Text] [Related]
12. Clinical success and quality of life with brimonidine 0.2% or timolol 0.5% used twice daily in glaucoma or ocular t hypertension: a randomized clinical trial. Brimonidine Outcomes Study Group I.
Javitt JC; Schiffman RM
J Glaucoma; 2000 Jun; 9(3):224-34. PubMed ID: 10877373
[TBL] [Abstract][Full Text] [Related]
13. Brimonidine 0.2% versus brimonidine Purite 0.15%: prophylactic effect on iop elevation after Nd:YAG laser posterior capsulotomy.
Yeom HY; Lee JH; Hong YJ; Seong GJ
J Ocul Pharmacol Ther; 2006 Jun; 22(3):176-81. PubMed ID: 16808678
[TBL] [Abstract][Full Text] [Related]
14. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily: 1-year results in glaucoma patients. Brimonidine Study Group.
Katz LJ
Am J Ophthalmol; 1999 Jan; 127(1):20-6. PubMed ID: 9932994
[TBL] [Abstract][Full Text] [Related]
15. 24-hour intraocular pressures with brimonidine purite versus dorzolamide added to latanoprost in primary open-angle glaucoma subjects.
Konstas AG; Karabatsas CH; Lallos N; Georgiadis N; Kotsimpou A; Stewart JA; Stewart WC
Ophthalmology; 2005 Apr; 112(4):603-8. PubMed ID: 15808251
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension.
Stewart WC; Day DG; Stewart JA; Schuhr J; Latham KE
Am J Ophthalmol; 2001 May; 131(5):631-5. PubMed ID: 11336939
[TBL] [Abstract][Full Text] [Related]
17. Preservative-free
Duru Z; Ozsaygili C
Cutan Ocul Toxicol; 2020 Mar; 39(1):21-24. PubMed ID: 31615279
[No Abstract] [Full Text] [Related]
18. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.
Schuman JS; Horwitz B; Choplin NT; David R; Albracht D; Chen K
Arch Ophthalmol; 1997 Jul; 115(7):847-52. PubMed ID: 9230823
[TBL] [Abstract][Full Text] [Related]
19. Twice-daily brinzolamide/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension.
Aung T; Laganovska G; Hernandez Paredes TJ; Branch JD; Tsorbatzoglou A; Goldberg I
Ophthalmology; 2014 Dec; 121(12):2348-55. PubMed ID: 25064721
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of brimonidine purite 0.1% and brimonidine purite 0.15%: a meta-analysis of two phase 3 studies.
Cantor LB; Liu CC; Batoosingh AL; Hollander DA
Curr Med Res Opin; 2009 Jul; 25(7):1615-20. PubMed ID: 19469697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
